Trial reportFrontiers in pharmacology2025
Effectiveness of diterpene ginkgolides meglumine injection after endovascular therapy for cardioembolic stroke: a randomized controlled trial.
Trial report in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endovascular interventional therapy is an important treatment method for cardioembolic stroke. Diterpene Ginkgolides Meglumine Injection (DGMI) may serve as an adjunct to endovascular interventional therapy for acute ischemic stroke. Methods: Patients with cardioembolic stroke receiving endovascular treatment were recruited and randomly assigned in a 1:1 ratio to either the DGMI treatment group or the control group. After the procedure, all patients routinely received management of risk factors and standard medication. Patients in the treatment group additionally received DGMI 25 mg diluted in 250 mL normal saline, administered by intravenous drip once daily for 14 consecutive days. NIHSS scores, modified Rankin Scale (mRS) scores, and hematologic parameters were measured, with adverse reactions monitored throughout. Results: A total of 104 patients completed the study. After 14 days of treatment, HCT was significantly lower and PT was significantly higher in the treatment group (( Conclusion: The combination of DGMI with endovascular therapy in patients with cardioembolic stroke is associated with reduced levels of coagulation biomarkers, improved neurological function, and better long-term prognosis, suggesting its potential as a complementary treatment following interventional procedures in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.